TOPICAL REVIEW

Glucocorticoids and renal Na\textsuperscript{+} transport: implications for hypertension and salt sensitivity

Robert W. Hunter, Jessica R. Ivy and Matthew A. Bailey

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

Abstract

The clinical manifestations of glucocorticoid excess include central obesity, hyperglycaemia, dyslipidaemia, electrolyte abnormalities and hypertension. A century on from Cushing’s original case study, these cardinal features are prevalent in industrialized nations. Hypertension is the major modifiable risk factor for cardiovascular and renal disease and reflects underlying abnormalities of Na\textsuperscript{+} homeostasis. Aldosterone is a master regulator of renal Na\textsuperscript{+} transport but here we argue that glucocorticoids are also influential, particularly during moderate excess. The hypothalamic–pituitary–adrenal axis can affect renal Na\textsuperscript{+} homeostasis on multiple levels, systemically by increasing mineralocorticoid synthesis and locally by actions on both the mineralocorticoid and glucocorticoid receptors, both of which are expressed in the kidney. The kidney also expresses both of the 11\beta-hydroxysteroid dehydrogenase (11\betaHSD) enzymes. The intrarenal generation of active glucocorticoid by 11\betaHSD1 stimulates Na\textsuperscript{+} reabsorption; failure to downregulate the enzyme during adaption to high dietary salt causes salt-sensitive hypertension. The deactivated glucocorticoid by 11\betaHSD2 underpins the regulatory dominance for Na\textsuperscript{+} transport of mineralocorticoids and defines the ‘aldosterone-sensitive distal nephron’. In summary, glucocorticoids can stimulate renal transport processes conventionally attributed to the renin–angiotensin–aldosterone system. Importantly, Na\textsuperscript{+} and volume homeostasis do not exert negative feedback on the hypothalamic–pituitary–adrenal axis. These actions are therefore clinically relevant and may contribute to the pathogenesis of hypertension in conditions associated with elevated glucocorticoid levels, such as the metabolic syndrome and chronic stress.

(Received 2 November 2013; accepted after revision 14 February 2014; first published online 17 February 2014)

Corresponding author

Matthew Bailey, PhD: University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK. Email: matthew.bailey@ed.ac.uk

Introduction

It is over 100 years since Harvey Cushing described the clinical consequences of severe glucocorticoid excess (Cushing, 1912) and although this syndrome remains rare, the cardinal features of central obesity, dyslipidaemia, impaired glucose metabolism and hypertension are increasingly prevalent in Western society (Batsis et al.)
Table 1. The integrated renal effects of glucocorticoids. The effects of glucocorticoids on renal haemodynamics and tubular transport function can oppose one another. This is discussed further in the main text.

<table>
<thead>
<tr>
<th>The effects of glucocorticoids on integrated renal function haemodynamic</th>
</tr>
</thead>
<tbody>
<tr>
<td>↑ renal blood flow</td>
</tr>
<tr>
<td>variable effect on renal vascular resistance</td>
</tr>
<tr>
<td>↑ filtration fraction</td>
</tr>
<tr>
<td>↑ glomerular filtration rate</td>
</tr>
<tr>
<td>water and electrolyte metabolism</td>
</tr>
<tr>
<td>diuresis</td>
</tr>
<tr>
<td>natriuresis or antinatriuresis – see main text</td>
</tr>
<tr>
<td>plasma volume contraction (or sometimes volume expansion – see main text)</td>
</tr>
<tr>
<td>kaliuresis</td>
</tr>
<tr>
<td>↑ renal acid excretion and metabolic alkalosis</td>
</tr>
<tr>
<td>phosphaturia</td>
</tr>
<tr>
<td>↑ amino acid transport</td>
</tr>
<tr>
<td>↑ sulphate transport</td>
</tr>
<tr>
<td>intermediate metabolism within the kidney</td>
</tr>
<tr>
<td>gluconeogenesis</td>
</tr>
<tr>
<td>ammoniagenesis</td>
</tr>
</tbody>
</table>

Integrated responses to glucocorticoids

The renal response to systemic glucocorticoid administration is well characterized (Table 1) but attempts to resolve these actions into specific tubular and vascular components are confounded by two phenomena: the pleiotropic effects of glucocorticoids and the promiscuity of steroid receptor–ligand interactions (Fig. 1).

The glucocorticoid receptor (GR) is ubiquitously expressed and systemic administration of glucocorticoids therefore changes many variables, including intermediary metabolism, cardiac output and systemic vascular resistance. This integrated response to glucocorticoids is clinically relevant but it is challenging to identify primary renal events (i.e. those occurring as a direct result of glucocorticoid signalling within the kidney) from secondary responses that are indirect and often countervailing. Thus, in some circumstances glucocorticoids promote renal Na⁺ retention. This is particularly evident for endogenous glucocorticoids and reflects activation of both GR and mineralocorticoid receptors (MR) in the renal tubule.

In other cases, glucocorticoids – particularly synthetic compounds – induce a powerful natriuresis (Table 1). The conventional explanation for this phenomenon is that the haemodynamic actions of glucocorticoids impair autoregulation, increase glomerular filtration rate (GFR) and, despite the best efforts of glomerulotubular balance, promote natriuresis and kaliuresis. The mechanisms that underpin these haemodynamic effects are not fully defined. Endogenous glucocorticoids certainly exert permissive effects that help maintain both renal blood flow (RBF) and GFR: both are reduced in adrenal insufficiency. Such underperfusion does not relate exclusively to hypotension as RBF is restored by steroid replacement but not by volume replacement alone (Mangos et al. 2003). The effect on renal haemodynamics of exogenous glucocorticoids is more complex and the mechanisms not resolved. Micropuncture evidence in rats found that prednisolone increased single nephron GFR due to dilatation of the glomerular arterioles, with the ultrafiltration coefficient and Starling forces across the glomerular capillary being unaffected (Baylis et al. 1990). Similar data were obtained in dogs (Hall et al. 1980). However, in humans, the glucocorticoid-induced increase in GFR must reflect an increased filtration fraction as RBF remains stable or even falls, causing increased renal vascular resistance (Connell et al. 1987). It is not clear what accounts for these differences but one possibility is differential sensitivity to the catabolic effect of synthetic glucocorticoids as increased renal delivery of amino acids can directly increase RBF (Baylis et al. 1990).

The second confounding phenomenon is the capacity for glucocorticoids to activate MR, exerting effects often antagonistic to their haemodynamic actions. For example, dogs infused with noradrenaline and adrenocorticotropic hormone (ACTH) become hypertensive and enter a negative Na⁺ and water balance. However, if the renal perfusion pressure is servo-controlled, hypertension is accompanied by Na⁺ retention (Woods et al. 1988). Similarly, chronic ACTH infusion into mice increases Na⁺ excretion (Dunbar et al. 2010) despite the fact that activation of MR and GR promotes Na⁺ reabsorption in the distal tubule (Bailey et al. 2009). These data underscore the dualistic effect of glucocorticoids, with the direct action on the renal tubules being over-ridden...
by haemodynamic processes that cause an increase in net urinary Na\textsuperscript{+} excretion.

Why do glucocorticoids exert these countervailing influences? Glucocorticoids induce a catabolic effect on systemic metabolism, promoting the conversion of protein, glycogen and triglyceride stores to amino acids, glucose and free fatty acids. The increase in GFR meets an increased demand for the excretion of waste products and contributes to the stress response. Teleologically, any direct stimulatory effect of glucocorticoids on tubular Na\textsuperscript{+} reabsorption would stabilize net excretion in the face of increased GFR, preserving salt and water balance in response to physiological stresses that threaten plasma volume. This effect is analogous to that induced by angiotensin II when activated in response to dietary Na\textsuperscript{+} restriction or hypovolaemia. Angiotensin II constricts the efferent arteriole to stabilize GFR in the face of reduced perfusion pressure and promotes Na\textsuperscript{+} retention by activation of transport proteins, including the thiazide-sensitive cotransporter (Ashek et al. 2012) and the epithelial Na\textsuperscript{+} channel (ENaC; Zaika et al. 2013).

However, the full extent of the physiological (and pathophysiological) role of glucocorticoids is both subtle and complex (Fig. 1). Glucocorticoids influence kidney development and the in utero programming of cardiovascular and renal phenotypes (Habib et al. 2011); they influence the pathogenesis of kidney injury (Rafiq et al. 2011) and they contribute to circadian variation in renal function: the glucocorticoid responsive protein, glucocorticoid-induced leucine zipper (GILZ), which features in the regulatory pathways of key Na\textsuperscript{+} transporters in the distal nephron (see Fig. 5), shows strong circadian oscillations in the kidney (Züber et al. 2009).

**Interaction between the hypothalamic–pituitary–adrenal axis and the renin–angiotensin–aldosterone system**

The HPAA can influence the RAAS at both systemic and local levels. For example, ACTH excess increases
the circulating mineralocorticoid ‘load’ in several ways. First, ACTH increases secretion of aldosterone by promoting cholesterol delivery to the mitochondria in the zona glomerulosa cells (Hattangady et al. 2012) and by enhancing CYP11B2 transcription (Takeda et al. 1996). Second, ACTH stimulates production of deoxycorticosterone, a weak mineralocorticoid that is physiologically significant when in excess (Mullins et al. 2009). The stimulatory effect of ACTH on aldosterone seems to be transient, but that on deoxycorticosterone sustained (Dunbar et al. 2010). Finally, ACTH may stimulate renin production in the juxtaglomerular apparatus (Oelkers et al. 1982), although this concept lacks much empirical support.

At a receptor level, glucocorticoids have equal, or perhaps greater, affinity for the MR than does aldosterone (Arriza et al. 1987). This concept is implicated in the hypokalaemia and hypertension of Cushing’s syndrome and is discussed in more detail below.

**Glucocorticoid signal transduction in the renal tubule**

**Pre-receptor steroid metabolism governs receptor specificity.** GR and MR share a high *in vitro* affinity for both classes of steroid (Arriza et al. 1987), but differ in their binding kinetics. The renal MR constitutes a high-affinity, low-capacity corticosteroid-binding site (formerly designated ‘type I’), $K_d$ 0.5–3 nM for both aldosterone and cortisol. GRs offer a low-affinity, high-capacity ‘type II’ site, $K_d$ 20–65 nM, for both steroids. The *in vivo* specificity of the GR and MR for their cognate ligands is, at least in part, a property conferred by the pre-receptor metabolism of glucocorticoids by the 11β-hydroxysteroid dehydrogenase isozymes: type 1 (11βHSD1) converts inactive 11-keto derivatives of glucocorticoids into physiologically active cortisol (corticosterone in rodents), and type 2 (11βHSD2) catalyses the reverse reaction (Chapman et al. 2013). Thus 11βHSD2 confers upon MR specificity for aldosterone that is inherently lacking: cortisol activates MR whereas...
cortisone does not (Fig. 2). Inhibition of 11βHSD2 activity (using derivatives of glycyrrhetinic acid, the active ingredient of liquorice) promotes Na⁺ reabsorption and potassium secretion in the distal nephron (Bailey et al. 2001). Genetic ablation of the enzyme, as occurs in apparent mineralocorticoid excess syndrome, causes low renin hypertension and hypokalaemia due in part to increased Na⁺ reabsorption in the distal nephron (Stewart et al. 1996; Bailey et al. 2008).

Nevertheless, the physiological role of 11βHSD2 in the kidney is more complex. The pre-receptor metabolism of glucocorticoids by the enzyme will protect MR but cells of the distal tubule also express GR. It is unlikely that these receptors are physiologically redundant and their activation will be influenced by 11βHSD2-mediated metabolism of cortisol. In heterologous expression systems, 11βHSD2 appears able to influence the subcellular localization of MR, possibly through a direct physical interaction. Furthermore, cortisone blocks the interaction between aldosterone and MR, suggesting that the ‘inactive’ 11-keto-glucocorticoids generated by 11βHSD2 may act as autocrine or paracrine MR antagonists (Odermatt et al. 2001). NAPH generation by 11βHSD2 can also alter the intracellular redox potential, locking MR–cortisol complexes in an inactive state (Funder, 2010). Thus, glucocorticoids can bind MR but the receptor is not physiologically activated unless excess reactive oxygen species are present. This adverse redox environment is generated in the kidney of salt-sensitive animals after a period of high Na⁺ intake: glucocorticoid-induced activation of MR promotes inflammation and fibrosis (Luther et al. 2012).

There is also the potential for interaction with sex steroids, as progesterone acts as a partial agonist for MR and GR (Arriza et al. 1987). Moreover, bona fide progesterone receptors are also expressed in the distal nephron, where they probably participate in the regulation of solute transport. Progesterone derived from the adrenal gland promotes renal potassium retention in male and ovariectomized female potassium-depleted mice (Elabida et al. 2011). This probably reflects direct signalling via the progesterone receptor as activation of GR or MR would be kaliuretic. Moreover, the potassium retention was blocked by RU486, an antagonist of the progesterone receptor. RU486 also antagonizes GR but the progesterone-induced potassium retention was not associated with induction of classic GR response genes.

Renal expression of glucocorticoid receptor, mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase isozymes. The expression patterns of MR and 11βHSD within the kidney are depicted in Fig. 3:

![Figure 3. Renal sites of MR and 11βHSD expression](image-url)
GR is widely expressed in the kidney, with mRNA being detected in most cells. In contrast, MR and 11βHSD2 have a more restricted distribution: co-localization of these in the connecting tubule and principal cells of the collecting duct defines the ‘aldosterone-sensitive distal nephron’ (ASDN). The expression of 11βHSD2 in the distal convoluted tubule (DCT) is less certain and it is probable that the enzyme is not expressed at high levels, if at all (Bostanjoglo et al. 1998; Campean et al. 2001). Although DCT cells express both GR and MR and are responsive to both corticosteroids, the conventional model of the ASDN does not apply in this segment. This is an important concept as the DCT reabsorbs more of the filtered Na⁺ load (~7%) than does the collecting duct (~5%). Abnormal glucocorticoid status could, via activation of the thiazide-sensitive transporter in the DCT, imperil Na⁺ retention and blood pressure homeostasis.

Several groups have proposed that 11βHSD2 abundance decreases along a gradient as one moves proximally from the cortical collecting duct, through the connecting tubule, to DCT. This has led to speculation that there may be an ‘ASDN proper’ in which aldosterone dominates regulation of Na⁺ transport through MR, and an intermediate segment expressing low levels of 11βHSD2 in which MR is activated by aldosterone under basal conditions and/or by glucocorticoids if they are present in excess, during activation of the HPAA or at certain periods during the circadian cycle (Gaeggeler et al. 2005). It is also possible that 11βHSD2 expression/activity is physiologically regulated by Na⁺ and K⁺ status (Thompson et al. 2000); DCT and the connecting tubule are plastic, homeostatically responsive epithelia capable of rapid remodelling of the molecular apparatus for Na⁺ transport.

$^{11}$β-Hydroxysteroid dehydrogenase 1 and the glucocorticoid-amplified proximal nephron. 11βHSD1 is located in the S3 proximal tubule (Fig. 3) and macula densa (Gong et al. 2008; Odermatt & Kratschmar, 2012). It has also been detected in the interstitial cells of the renal medulla (Castello et al. 1989; Rundle et al. 1989). As these cells lack the hexose-6-phosphate dehydrogenase and cannot generate NADPH, 11βHSD1 may therefore act as a dehydrogenase here, catalysing the same reaction as 11βHSD2 (Gomez-Sanchez et al. 2008). The urinary steroid profile following siRNA knockdown of medullary 11βHSD1 suggests that this is not correct and 11βHSD1 acts predominantly as a reductase (Liu et al. 2008). This leads to the concept of a ‘glucocorticoid-amplified proximal nephron’ and detailed physiological examination of 11βHSD1 activity in the renal tubule is required. Data are surprisingly scarce but downregulation of renal 11βHSD1 is an adaptive response to either salt loading or increased blood pressure (Dunbar et al. 2010). Failure to transcriptionally repress the encoding gene, hsd11b1, contributes to the pathogenesis of salt-sensitive hypertension. This phenomenon was demonstrated in innovative studies using the Dahl salt-sensitive (DSS) rat and a conomic control strain (DSS-13BN) with attenuated salt sensitivity of blood pressure. Renal medullary expression of 11βHSD1 was downregulated in response to high dietary salt in DSS-13BN but not in DSS rats. The authors hypothesized that failure to downregulate 11βHSD1 contributed to renal Na⁺ retention and hypertension. To test this hypothesis, knockdown of 11βHSD1 expression/activity was induced by injecting siRNA into the renal medulla in vivo. hsd11b1 knockdown attenuated salt-sensitive hypertension in the DSS rats (Liu et al. 2008). The molecular mechanism underpinning the rescue of salt-sensitive blood pressure was not determined. It may be that 11βHSD1 knockdown had a direct impact on Na⁺ transport processes in the medullary tubular epithelium (i.e. on NKCC2 function in the thick ascending limb of Henle’s loop). There is no consensus in the literature concerning the effect of glucocorticoids on NKCC2 activity, with both transcriptional repression of slc12a1 (Bailey et al. 2009) and increased abundance of the protein (Frimdt & Palmer, 2012) being reported. Nevertheless, hsd11b1 knockdown in the renal medulla resulted in a reduction in the concentration of corticosterone in the urine. This raises the possibility that 11βHSD1 in the interstitial cells of the medulla exerts a paracrine effect on transport processes in the distal nephron by altering the concentration of active glucocorticoids in the downstream tubular fluid and/or peritubular capillaries.

Glucocorticoid receptor in the distal nephron. Classical studies of receptor–ligand interactions in collecting duct cells in vitro demonstrate that mineralocorticoids can bind to the GR. Indeed, binding assays indicate that physiological concentrations of aldosterone would induce a low level of GR occupancy, but the biological significance of this is not clear (Gaeggeler et al. 2005). An interaction between aldosterone status and the GR has been demonstrated in mouse and rat kidneys (Ackermann et al. 2010), using nuclear translocation as a proxy for receptor activation. Contrary to our understanding of the ASDN, suppression of aldosterone by dietary NaCl loading resulted in a reduction in the nuclear localization of GR in the ASDN whereas MR localization was not affected. Conversely, adrenalectomy resulted in the loss of nuclear MR and GR in all nephron segments. The nuclear MR signal was restored in all nephron segments by physiological doses of corticosterone. The GR signal was restored in most nephron segments but not in the ASDN. Furthermore, in a colonic cell line expressing both receptors (an unusual phenomenon in epithelial cell lines),
GR activation did not itself induce ENaC but was a pre-requisite for the full MR-mediated response to aldosterone (Bergann et al. 2011). Similar findings have been reported in neuronal cell lines (Tsugita et al. 2009). The interaction between the receptors is not understood but GR may be sine qua non for formation of the MR/MR homodimer or may even form a heterodimer with MR (Fig. 2), as is suggested by FRET microscopy (Nishi et al. 2004).

These data challenge our conventional view of the steroid control of Na\(^+\) transport in the ASDN and the consequences for Na\(^+\) transport are not clear. If glucocorticoids, via GR, physiologically regulate MR, an important homeostatic role for 11\(\beta\)HSD2 may be to control intracellular glucocorticoid concentration and thereby govern GR activation.

**Signal transduction downstream of steroid receptor activation**

Activated steroid receptors translocate to the nucleus, where they act as transcription factors. There is considerable overlap in the GR and MR response genes, providing an additional mechanism through which both classes of steroid can activate a common set of biological effector pathways.

**Genomic responses to glucocorticoids: well-characterized pathways.** GR activation in the collecting duct stimulates the transcription of Sgk1 and GILZ (Muller et al. 2003; Nguyen Dinh Cat et al. 2009). However, the role of Sgk1 in the renal response to glucocorticoids in vivo remains obscure. Dexamethasone increases the abundance of Sgk1 transcripts in whole kidney homogenates. Our data indicate that Sgk1 is physiologically active: dexamethasone increases the phosphorylation of the Sgk1 target NDRG1 (Fig. 4). Dexamethasone does not, however, increase Sgk1 expression in isolated cortical collecting ducts (Muller et al. 2003); Sgk1 expression in the distal renal tubule was not altered in response to over-expression of GR in the collecting duct (Nguyen Dinh Cat et al. 2009). These observations suggest that whereas Sgk1 participates in the response to glucocorticoids in some kidney cells, it does not do so in the ASDN, where some (yet unknown) mechanisms preserve Sgk1 as an aldosterone-responsive gene. Dexamethasone upregulates NHE3 activity in cultured renal cells in an Sgk1-dependent fashion, providing in vitro evidence that Sgk1-dependent pathways may participate in glucocorticoid-regulated solute transport in the proximal nephron (Wang et al. 2007).

Both Sgk1 and GILZ are also classic MR response genes (Fig. 5). The Sgk1-Nedd4-2-ENaC pathway provides

---

**Figure 4.** Dexamethasone increases the abundance of phosphorylated NDRG1 (P-NDRG1-Th^346,356,366) in whole mouse kidney, indicative of increased Sgk1 activity. C57BL/6 mice were treated with dexamethasone (1 mg kg\(^{-1}\)) or vehicle (0.9% saline) and kidneys collected after 6 h. A, kidneys were probed with antibodies to the phosphorylated form of NDRG1 (P-NDRG1-Th^346,356,366) or total NDRG1 (T-NDRG1). NDRG1 is a substrate for SGK1 and this phosphoprotein is a surrogate indicator of SGK1 activity. B, densitometry analysis indicated P-NDRG1 was significantly increased in the dexamethasone-treated group but there was no change in the T-NDRG1. Data are means \(\pm\) s.e.m., \(n = 6\). *

© 2014 The Authors. The Journal of Physiology © 2014 The Physiological Society
the canonical mechanism whereby aldosterone stimulates Na$^+$ reabsorption in the principal cell (Snyder et al. 2002); the Sgk1-Nedd4–2 pathway also operates in the DCT to stimulate NCC (Arroyo et al. 2011). In cultured collecting duct (mpkCCD) cells, GILZ participates in the regulation of ENaC activity by aldosterone (Soundararajan et al. 2005).

**Genomic responses to glucocorticoids: an unbiased approach.** We have made a systematic attempt to identify the renal transcriptional response to glucocorticoids in mice exposed to 12 days of exogenous ACTH. mRNA prepared from whole kidneys was hybridized with an Affymetrix GeneChip (Santa Clara, CA, USA), and the results subjected to a pathway analysis (Dunbar et al. 2010). This model predominantly reflects glucocorticoid-mediated signalling, the stimulation by ACTH of aldosterone production (vide supra) being transient (Dunbar et al. 2010). A large number of genes were differentially regulated, including known targets such as Sgk1 as well as novel gene pathways concerned with organic anion/cation transport, vitamin D, calcium and xenobiotic metabolism.

**The WNK-SPAK cascade.** The WNK-SPAK kinase network acts as a master regulator of electrolyte transport in the distal renal tubule, and can transduce mineralocorticoid signals (Hoorn et al. 2011). Sgk1 phosphorylates WNK4 at ser$^{1169}$, thus relieving inhibition by WNK4 of downstream targets, including NCC, ENaC and ROMK (Ring et al. 2007; Rozansky et al. 2009).

However, GR can also regulate WNK signalling. WNK4 expression is reduced when GR is overexpressed in the collecting duct (Nguyen Dinh Cat et al. 2009) and GR

---

**Figure 5. Paradigm of mineralocorticoid signalling: regulation of ENaC in the principal cell**

Aldosterone regulates ENaC through MR-binding dependent promotion of SGK-1 expression and ENaCα expression. Two phosphorylation steps, mediated by TORC2 and PDK1, activate SGK1 (SGK1-P-P*). These kinases are activated by the PI3K system. SGK1 phosphorylates Nedd4/2, which is an ubiquitin ligase enzyme that binds ENaC and marks it for withdrawal from the apical membrane and subsequent degradation. SGK1-dependent phosphorylation inhibits Nedd4/2-ENaC binding and promotes the maintenance of ENaC in the membrane. Glucocorticoids are prevented from activating MR in the presence of high levels of 11βHSD2. GILZ expression is also increased upon aldosterone stimulation and is thought to stabilize SGK1. Red connectors represent inhibition through phosphorylation or ubiquitinylation, while green arrows indicate stimulation by phosphorylation or otherwise. Black arrows indicate movement of ions or change to phosphorylated state. A, aldosterone; ENaC, epithelial Na$^+$ channel; G, glucocorticoids; 11βHSD1/2, 11β-hydroxysteroid dehydrogenase 1/2; MR, mineralocorticoid receptor; P, phosphorylation; U, ubiquitylation.

© 2014 The Authors. The Journal of Physiology © 2014 The Physiological Society
negatively regulates WNK4 transcription in mpkDCT cells and in the murine DCT in vivo (Mu et al. 2011) (vide infra). Basal WNK4 mRNA expression is higher in mice lacking GR in the distal nephron, suggesting that endogenous glucocorticoids exert a tonic antinatriuretic effect through their effects on WNK signalling (Mu et al. 2011).

Glucocorticoid effects on tubule Na\(^{+}\) transport

The systemic administration of glucocorticoids induces effects on solute transport processes along the length of the renal tubule. For example, dexamethasone treatment in rats causes an increase in the abundance of NHE3, NCC, NKCC2, the full-length isoform of \(\alpha\)-ENaC and the cleaved isoform of \(\gamma\)-ENaC in whole kidney homogenates (Frindt & Palmer, 2012). Glucocorticoids influence cellular morphology and proliferation in the distal renal tubule, causing amplification of the basolateral membranes of the principal cells in the cortical collecting tubules in the rabbit (Wade et al. 1979). However, these studies are unable to discriminate between the specific effects of glucocorticoid signalling in renal tubular cells and a ‘passive’ response to glucocorticoid-induced changes in systemic haemodynamics and/or intermediate metabolism.

Glucocorticoid effects in the proximal tubule

Regulation of NHE3 and Na\(^{+}\)-P, cotransporter 2. In the rat glucocorticoids stimulate Na\(^{+}\) bicarbonate reabsorption by activating NHE3 (Zallocchi et al. 2003) and suppress sodium phosphate cotransport by Na\(^{+}\)-P, cotransporter 2 (Loffing et al. 1998). These events contribute to glucocorticoid-induced increases in the renal excretion of acid and phosphate (Table 1).

Glucocorticoid effects in the distal convoluted tubule

Glucocorticoids stimulate NaCl reabsorption in the DCT. The underlying molecular mechanisms show the DCT to be a site at which several key natritropic signals interact. In a mouse model of salt-sensitive hypertension with sympathetic activation, an epigenetic interaction between adrenergic and glucocorticoid signalling is indicated. This effect is mediated by the WNK kinases and results in the regulation of NCC expression, phosphorylation and transport activity (Mu et al. 2011). \(\beta\)-adrenergic stimulation activated NCC by suppressing WNK4 expression through a GR-dependent mechanism. Activated \(\beta_2\)-adrenoceptors induced histone acetylation at negative glucocorticoid response elements in the WNK4 promoter, enhancing GR binding. There was corresponding negative regulation of Wnk4 by GR in the DCT in vivo: adrenalectomy or a GR antagonist abolished the inhibitory effect of noradrenaline on Wnk4 mRNA expression (and this was restored by dexamethasone in the case of adrenalectomy).

As WNK4 is itself a negative regulator of NCC activity, these findings support a model in which GR activation in the DCT tonically stimulates NaCl reabsorption. Consistent with this, basal Wnk4 mRNA abundance was higher in mice lacking GR in the distal nephron.

Glucocorticoid effects in the aldosterone-sensitive distal nephron: in vitro and in vivo data

The ability of glucocorticoids to stimulate electrogenic Na\(^{+}\) transport in the collecting ducts has been demonstrated in vitro using cultured cell lines that faithfully maintain many of the in vivo characteristics of principal cells (Naray-Fejes-Toth & Fejes-Toth, 1990; Laplace et al. 1992; Bens et al. 1999; Gaegger et al. 2005). In mCCD\(_{di}\) cells, corticosterone stimulates amiloride-sensitive transport even in the presence of intact 11\(\beta\)HSD2 (Gaegger et al. 2005), albeit at higher concentrations than aldosterone (K\(_{50} = 18 ~\text{nmol}\) for corticosterone; 0.52 \text{nmol} for aldosterone). High concentrations of dexamethasone stimulate this current via an RU486-sensitive pathway, suggesting that this is a consequence – at least in part – of GR activation. The mechanisms whereby GR stimulates Na\(^{+}\) transport in the collecting duct remain to be established: regulation of endothelin-1 expression has been implicated in vitro (Stow et al. 2012).

Glucocorticoid effects on Na\(^{+}\) transport in the ‘aldosterone-sensitive distal nephron’ in vivo. Despite the robust in vitro data, a direct demonstration that glucocorticoids physiologically activate ENaC in vivo has been lacking. Seven days of treatment with dexamethasone increased the abundance of the full-length isoform of \(\alpha\)-ENaC in rat kidney, but had no effect on electrogenic Na\(^{+}\) transport in split open collecting ducts (Frindt & Palmer, 2012). Mice heterozygotes for a null mutation in Hsd11b2 (the gene encoding 11\(\beta\)HSD2) have salt-sensitive blood pressure associated with elevated levels of circulating glucocorticoids (Bailey et al. 2011). Salt loading induced hypokalaemia in hsd11b2\(^{+/−}\) mice, and the trans-tubular potassium gradient >7 indicated enhanced ‘mineralocorticoid’ activity in the distal nephron. The salt sensitivity and hypokalaemia were both corrected by GR antagonism but not by MR antagonism, suggesting that GR activation might exert a pathophysiological role in the ASDN.

The MR knockout mouse provides further evidence of glucocorticoids exerting mineralocorticoid effects in the distal nephron. Global constitutive knockout in MR is fatal; the animals die from excessive urinary solute losses at about day 10, indicating that GR is not able
to completely compensate for the lack of MR (Berger et al. 1998). However, glucocorticoids are capable of a partial compensation: triamcinolone treatment enhanced ENaC expression and activity in salt-supplemented MR knockout mice (Schulz-Baldes et al. 2001).

The direct effects of GR signalling in the distal nephron has been investigated using two transgenic mouse models: Ksp-Cre$^+$ GR$^{loxP/loxP}$ mice, in which GR was specifically and constitutively deleted in the AQP2-positive distal nephron (Goodwin et al. 2010), and Hoxb7-tetON2-hGR mice in which GR was conditionally overexpressed in cells of collecting duct lineage (Nguyen Dinh Cat et al. 2009). Loss of GR from the distal nephron had no effect on the response to chronic dexamethasone, which induced a rise in blood pressure and a natriuresis that was indistinguishable from that in wild-type mice (Goodwin et al. 2010). However, basal blood pressure was higher in Ksp-Cre$^+$ GR$^{loxP/loxP}$ mice, raising the possibility that GR activity in the ASDN participates in blood pressure homeostasis in the ‘normal healthy’ adult. This being a constitutive knockout, a developmental effect cannot be discounted. Overexpression of GR in the distal nephron had no effect on net urinary Na$^+$ or K$^+$ excretion, although there was a reduction in urinary aldosterone indicative of compensatory RAAS inhibition (Nguyen Dinh Cat et al. 2009). There was a clear transcriptional response to GR overexpression (discussed above). Taken together, these data suggest that GR-mediated signalling may modulate Na$^+$ transport in the collecting duct, but the regulation of net renal Na$^+$ excretion is physiologically dominated

Figure 6. Interactions between the RAAS and the HPAA
Dashed arrows (with filled circles at the head) represent negative feedback loops. Red arrows are potential sites of crosstalk between the RAAS and the HPAA. Interactions arise at multiple levels: pre-receptor (changes in ligand availability), receptor (receptor–ligand promiscuity) and post-receptor (common second messenger systems). HPAA activation can increase the activity of 11βHSD2 and inhibit 11βHSD1. The other potential routes of crosstalk are discussed in the main text. ACTH, adrenocorticotrophic hormone; AngII, angiotensin II; CRH, corticotrophin releasing hormone; DOC, deoxycorticosterone; HPAA, hypothalamic–pituitary–adrenal axis; 11βHSD1/2, 11β-hydroxysteroid dehydrogenase 1/2; MR, mineralocorticoid receptor; RAAS, renin–angiotensin–aldosterone system.
Glucocorticoids and renal Na⁺ transport

Implications for hypertension and salt sensitivity in humans

The renal tubules possess the molecular apparatus requisite for glucocorticoid-responsive Na⁺ transport. The expression of 11βHSD1 and 11βHSD2 will influence these processes by regulating local glucocorticoid concentrations. Several lines of evidence challenge the conventional role of renal 11βHSD2 as a mere enzymatic guardian of the MR. Equally compelling, is evidence showing stimulation by glucocorticoids of Na⁺ reabsorption at several sites along the nephron. More provocatively, experiments in cell lines and in native kidney indicate that GR has an important permissive role for aldosterone signalling at MR. The HPAA is thus able to influence renal Na⁺ excretion at multiple levels (Fig. 6) – and such regulation escapes the negative feedback mechanisms inherent within the RAAS.

However, is this relevant for human health? Many of the mechanisms whereby glucocorticoids cause hypertension reside in the vasculature, and central and autonomic nervous systems, but there is a clear contribution from an antinatriuretic effect in the renal tubules. This is clinically important: salt-sensitive humans have an enhanced stress-induced activation of the HPAA (Weber et al. 2003) and attenuated glucocorticoid clearance (Kerstens et al. 2008). Glucocorticoids stimulate electrogenic Na⁺ transport in humans when present in excess, as in Cushing’s syndrome. We do not know, however, if this contributes to hypertension in states of moderate glucocorticoid excess or in the metabolic syndrome, where the tissue availability of active glucocorticoid is enhanced (Pereira et al. 2012). Hsd11b2 gene polymorphisms are associated with salt sensitivity in blood pressure in normotensive and hypertensive subjects, suggesting that glucocorticoids can breach the 11βHSD2 barrier even when they are not present in vast excess.

The molecular pathways whereby glucocorticoids contribute to salt-sensitive hypertension have been elucidated in mice. These studies provide a mechanistic explanation for the long-recognized ability of combined glucocorticoid and adrenergic stimulation to exert tubular antinatriuretic effects. Mechanisms in the distal nephron predominate: the NCC is activated during sympathetic stimulation (Mu et al. 2011) and ENaC is increased in 11βHSD2 heterozygotes (Craigie et al. 2012). These pathways are attractive therapeutic targets to ameliorate the salt-sensitive hypertension associated with chronic stress and other states of sympathetic and HPAA activation in humans. There is also a pressing clinical need to develop a mechanistic understanding of the effects of renal 11βHSD1 activity on Na⁺ transport. Systemic 11βHSD1 inhibitors are in development for use as modifiers of cardiovascular risk in obesity, type 2 diabetes mellitus and the metabolic syndrome (Hughes et al. 2008; Hadoke et al. 2009), conditions in which salt-sensitive hypertension is prevalent (Hall, 2003; Fujita, 2010). One potential side-benefit of 11βHSD1 inhibition in such cases might be an improvement in salt sensitivity because of diminished active glucocorticoid generation in the renal medulla. An antihypertensive effect of 11βHSD1 inhibitors has recently been reported in a clinical trial and in the spontaneously hypertensive rat (Bauman et al. 2013).

Conclusion

Conditions associated with modest elevations in circulating glucocorticoids are common. Moreover, the widespread therapeutic use of GR agonists may flatten the dynamic regulation of the HPAA with deleterious consequences for renal Na⁺ homeostasis. Glucocorticoids regulate Na⁺ transport in the proximal and distal renal tubule and, in particular, can stimulate Na⁺ reabsorption in the post-macular segments. 11βHSD2 activity is low in the DCT, which is emerging as a critical site for the regulation of renal Na⁺ excretion by various signalling pathways, including glucocorticoids. These effects have implications for human health and disease, with the potential to contribute to the pathogenesis of Na⁺-sensitive hypertension in the metabolic syndrome and in chronic stress.

References


### Additional information

#### Competing interests

None declared.

#### Author contributions

All authors approved the final version for publication.

#### Acknowledgements

We thank Dr Chris Kenyon for his critical appraisal of the manuscript and for Fig. 1, Prof. Stuart Wilson for discussion of data, The British Heart Foundation Centre of Research Excellence Award and Kidney Research UK for research funding. RWH was supported by a Clinical Research Fellowship from The Wellcome Trust; JRI by a British Heart Foundation 4-year PhD studentship.